loading
Grant of Options
10 September 2015
Futura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology, announces that on 9 September 2015 it granted options over a total of 400,000 ordinary shares of 0.2p each in the Company to Directors as detailed below.
| Director | Number of options granted |
Exercise price |
Exercise period |
Total number of options held following notification |
Total number of ordinary shares held |
| J H Barder | 250,000 | 30.0p | 1 Oct 2017 - 30 Sep 2022 | 1,500,000 | 1,008,830 |
| D A Martin | 150,000 | 30.0p | 1 Oct 2017 - 30 Sep 2022 | 869,279 | 280,000 |
The new options were granted under the Futura Medical plc Unapproved Share Option Scheme.
The main vesting condition of the options is that the Directors remain employed with the Company as at the date of exercise.
For further information please contact:
Futura Medical plc
James Barder, Chief Executive
Angela Hildreth, Finance Director and COO
+44 (0) 1483 685 670
james.barder@futuramedical.com
angela.hildreth@futuramedical.com
www.futuramedical.com
Nominated Adviser:
N+1 Singer
Aubrey Powell / Liz Yong
Tel: +44 (0) 20 7496 3000
For media enquiries please contact:
Buchanan
Mark Court / Sophie Wills /
Stephanie Watson / Tilly Abraham
Tel: +44 (0) 20 7466 5000
Notes to editors:
Futura Medical plc
Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.
Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.
